SAB Biotherapeutics (SABS) EBITDA (2021 - 2026)

SAB Biotherapeutics has reported EBITDA for 6 years, with the latest figure at -$20.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 85.64% year-over-year to -$20.0 million; the trailing twelve-month figure through Mar 2026 stood at -$58.2 million (down 37.56% YoY), and the FY2025 full-year result was $13.6 million, up 139.68% from the prior year.
• EBITDA for Q1 2026 stood at -$20.0 million, down from -$15.8 million in the prior quarter.
• The five-year high for EBITDA was $17.1 million in Q4 2022, with the low at -$20.0 million in Q1 2026.
• Historically, EBITDA has averaged -$9.1 million across 5 years, with a median of -$10.0 million in 2024.
• The largest YoY upside for EBITDA was 333.21% in 2022 against a maximum downside of 924.07% in 2022.
• SAB Biotherapeutics' EBITDA stood at $17.1 million in 2022, then plunged by 210.2% to -$18.9 million in 2023, then soared by 46.97% to -$10.0 million in 2024, then tumbled by 57.56% to -$15.8 million in 2025, then slipped by 26.81% to -$20.0 million in 2026.
• The last three EBITDA figures came in at -$20.0 million (Q1 2026), -$15.8 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.